Navigation Links
NOVAVAX to Present at Oppenheimer 20th Annual Healthcare Conference

ROCKVILLE, Md., Oct. 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Oppenheimer 20th Annual Healthcare Conference. Dr. Singhvi's presentation will take place at 3:20 pm local time on November 3, 2009 at the Waldorf=Astoria, New York, NY. Dr. Singhvi will provide an overview of the company's business strategy and research and development progress. A link to the live presentation can be accessed via the Company website at under the Investors tab. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

About the Oppenheimer 20th Annual Healthcare Conference

The Oppenheimer 20th Annual Healthcare Conference will take place at the Waldorf=Astoria in New York City, November 3-4, 2009. This conference will present a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries. Over 19 years, the Oppenheimer Healthcare Conference has become a highly valuable investor conference in this sector. Through formal company presentations and panels, attendees will gain insight from, and access to, industry leaders.

The Companies participating in this conference will address topical issues such as health reform, Medicare and Medicaid, generic drug regulation, development of new blockbuster pharmaceutical and biotechnology products, product safety and patent issues, cross-border reimportation, Food and Drug Administration policy, managed care, and the current M&A environment.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website:

SOURCE Novavax, Inc.

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA
2. Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
3. Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program
4. Novavax CEO to Present at the World Vaccine Congress 2009, Lyon, France
5. Novavax Announces Board of Director Changes
6. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
7. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
8. Novavax Reports Second Quarter 2009 Financial Results
9. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
10. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
11. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
Post Your Comments:
(Date:12/1/2015)... SEATTLE , Dec. 1, 2015 Today ... headquarters in Seattle,s South Lake ... northwest corner of Mercer Street and Westlake Avenue North, ... to the Allen Institute for Brain Science and the ... Allen , philanthropist and founder of the Allen Institute. ...
(Date:12/1/2015)... , Dec. 1, 2015 Oxford Finance LLC ... to life sciences and healthcare services companies, today announced ... loan with MDRejuvena, Inc. ("the Company"). Proceeds from the ... development of the Company,s Rejuvaphyl™ and daily skincare products. ... is the MDRejuvena brand of high potency skincare products ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... announces Park NX10 SICM Module, an add-on scanning ion conductance microscopy module to ... of SICM to an AFM. , Park SICM benefits virtually all materials characterization ...
(Date:12/1/2015)... Dec. 1, 2015 Cepheid (Nasdaq: CPHD ... at the Piper Jaffray Healthcare Conference in ... Company is reaffirming its outlook for the fourth quarter ... addition to discussing longer term business model expectations. ... Officer.  "We continue to be the fastest growing company ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):